Background and aims A study on the effect of the phyto-immunomodulator BNO 1030 (Bionorica SE, Germany) on the frequency of acute respiratory infections (ARI) in 128 children aged 3 to 14 years.

Methods Determining the level of expression of the transcription factor NF-κB in peripheral blood lymphocytes by flow cytometry.

Results After the BNO 1030 therapy lasted for 4 weeks, a significant decrease in ARI multiplicity by 1.7 times, a modest shortening of the duration of follow-up ARI (1.4 days on average) was observed over the next 12 months, and the incidence of mild cases of ARI was increased (from 57% to 75%) decreased the number of antibiotic prescriptions (from 3.4±0.4 to 1.6±0.2 times). After therapy with BNO 1030, there was a decrease in the activity of the transcription factor NF-ìB from 44.4±2.4 units to 32.4±3.1 units (t-=3.06; p= 0.002).

Conclusions The BNO 1030 has a significant prophylactic effect, preventing the onset of ARI in children. This clinical effect is associated with inhibition of the pro-inflammatory potency of the child’s body.